Literature DB >> 22553267

Introduction to drug pharmacokinetics in the critically ill patient.

Brian S Smith1, Dinesh Yogaratnam2, Kimberly E Levasseur-Franklin3, Allison Forni4, Jeffrey Fong5.   

Abstract

Despite regular use of drugs for critically ill patients, overall data are limited regarding the impact of critical illness on pharmacokinetics (PK). Designing safe and effective drug regimens for patients with critical illness requires an understanding of PK. This article reviews general principles of PK, including absorption, distribution, metabolism, and elimination, and how critical illness can influence these parameters. In the area of drug absorption, we discuss the impact of vasopressor use, delayed gastric emptying and feeding tubes, and nutrient interactions. On the topic of drug distribution, we review fluid resuscitation, alterations in plasma protein binding, and tissue perfusion. With drug metabolism, we discuss hepatic enzyme activity, protein binding, and hepatic blood flow. Finally, we review drug elimination in the critically ill patient and discuss the impact of augmented renal clearance and acute kidney injury on drug therapies. In each section, we highlight select literature reviewing the PK impact of these conditions on a drug PK profile and, where appropriate, provide general suggestions for clinicians on how to modify drug regimens to manage PK challenges.

Entities:  

Mesh:

Year:  2012        PMID: 22553267     DOI: 10.1378/chest.11-1396

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  53 in total

1.  Argatroban for Heparin-Induced Thrombocytopenia during Venovenous Extracorporeal Membrane Oxygenation with Continuous Venovenous Hemofiltration.

Authors:  Jonathan H Sin; Natasha D Lopez
Journal:  J Extra Corpor Technol       Date:  2017-06

2.  Benzodiazepine-associated delirium in critically ill adults.

Authors:  Irene J Zaal; John W Devlin; Marijn Hazelbag; Peter M C Klein Klouwenberg; Arendina W van der Kooi; David S Y Ong; Olaf L Cremer; Rolf H Groenwold; Arjen J C Slooter
Journal:  Intensive Care Med       Date:  2015-09-24       Impact factor: 17.440

3.  A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients.

Authors:  Shamir N Kalaria; Mathangi Gopalakrishnan; Emily L Heil
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 4.  [Antibiotic dosing for renal function disorders and continuous renal replacement therapy].

Authors:  Erik Michael; Detlef Kindgen-Milles
Journal:  Anaesthesist       Date:  2015-04       Impact factor: 1.041

5.  Dosing nucleoside reverse transcriptase inhibitors in adults receiving continuous veno-venous hemofiltration.

Authors:  Milena M McLaughlin; Abeer T Ammar; Lana Gerzenshtein; Kimberly K Scarsi
Journal:  Clin Drug Investig       Date:  2015-04       Impact factor: 2.859

Review 6.  Pharmacokinetics in sepsis.

Authors:  M Charlton; J P Thompson
Journal:  BJA Educ       Date:  2018-11-09

7.  Whole-body physiology-based pharmacokinetics of caspofungin for general patients, intensive care unit patients and hepatic insufficiency patients.

Authors:  Qian-Ting Yang; Ya-Jing Zhai; Lu Chen; Tao Zhang; Yan Yan; Ti Meng; Lei-Chao Liu; Li-Mei Chen; Xue Wang; Ya-Lin Dong
Journal:  Acta Pharmacol Sin       Date:  2018-05-31       Impact factor: 6.150

8.  Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia.

Authors:  Simone M C Spoorenberg; Vera H M Deneer; Jan C Grutters; Astrid E Pulles; G P Paul Voorn; Ger T Rijkers; Willem Jan W Bos; Ewoudt M W van de Garde
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

Review 9.  The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review.

Authors:  Raymond Vanholder; Eva Schepers; Anneleen Pletinck; Evi V Nagler; Griet Glorieux
Journal:  J Am Soc Nephrol       Date:  2014-05-08       Impact factor: 10.121

10.  Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults.

Authors:  Amira A Bhalodi; Pavlos K Papasavas; Darren S Tishler; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.